Aventis Selects Lantus As U.S. Tradename For Insulin Glargine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Aventis is expecting to use the tradename Lantus in the U.S. as well as certain foreign markets for insulin glargine, the company’s biosynthetic once-daily basal insulin for use in patients with type 1 or type 2 diabetes. FDA is "looking favorably" on the potential name, the company said.